NIH Releases New Version of COVID-19 Treatment Guidelines
October 10, 2023
The COVID-19 Treatment Guidelines Panel (the Panel) has published an update to the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Important changes include:
- The Panel added 2 new sections, Abatacept and Infliximab, to discuss the available clinical data on the use of these agents to treat certain hospitalized patients with COVID-19.
- Therapeutic Management of Hospitalized Adults With COVID-19 provides updated information on the use of abatacept, infliximab, remdesivir, sarilumab, and tofacitinib to treat COVID-19 in certain hospitalized adults.
- The Panel has updated the recommendation for use of Metformin in nonhospitalized patients with COVID-19. There is currently insufficient evidence to recommend either for or against the use of metformin in these patients. The Panel also added information about a secondary endpoint from the COVID-OUT study to the text and clinical data table.
- In the section on Antithrombotic Therapy in Patients With COVID-19, the Panel revised the recommendation on the use of an intermediate dose of anticoagulation for venous thromboembolism prophylaxis in hospitalized patients with COVID-19 who require intensive care unit-level care. This change is based on results from the recently published ANTICOVID trial.
- Minor updates were made to several other Guidelines sections, including Ritonavir-Boosted Nirmatrelvir (Paxlovid), Special Considerations in People Who Are Immunocompromised, and Influenza and COVID-19.
For a full list of updates, please see What's New in the Guidelines on the COVID-19 Treatment Guidelines website.